Altorki, Nasser K. http://orcid.org/0000-0001-9754-9945
Walsh, Zachary H.
Melms, Johannes C. http://orcid.org/0000-0002-5410-6586
Port, Jeffery L.
Lee, Benjamin E.
Nasar, Abu
Spinelli, Cathy
Caprio, Lindsay
Rogava, Meri
Ho, Patricia http://orcid.org/0000-0002-4622-8188
Christos, Paul J.
Saxena, Ashish
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Bhinder, Bhavneet
Ager, Casey
Amin, Amit Dipak http://orcid.org/0000-0002-2613-2082
Sanfilippo, Nicholas J.
Mittal, Vivek http://orcid.org/0000-0002-4764-7413
Borczuk, Alain C. http://orcid.org/0000-0001-6807-8064
Formenti, Silvia C. http://orcid.org/0000-0002-8227-8924
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
McGraw, Timothy E. http://orcid.org/0000-0001-9748-263X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5UH3CA244697, CA271545-01A1, CA258829, CA280414, CA266446, CA274506)
U.S. Department of Defense (W81XWH2110309)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 23 August 2023
Accepted: 4 December 2023
First Online: 19 December 2023
Change Date: 3 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-44575-3
Competing interests
: N.K.A. reports stock options from TMRW, Angiocrine Bioscience, and View Point Medical; research advisory committee for AstraZeneca. J.L.P. reports leadershi1 and stock options from TMRW, Angiocrine Bioscience and View Point Medical. B.E.L. reports personal fees from AstraZeneca. A.S. reports personal fees from AstraZeneca, Blueprint Medicines, Genentech, Medtronic and Takeda. S.C.F. grants from Bristol Myers Squibb, Varian, Merck, Eisai, Elililly, Janssen and Regeneron; and personal fees from Accuray, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serano/Merck, GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian, and ViewRay. B.l. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck, and has received research funding from Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, lmmunocore, and Synthekine. The other authors declare no competing interests.